# Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose.

> **NCT07545226** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Amgen** · enrollment: 400 (estimated)

## Conditions studied

- Healthy Participants

## Interventions

- **DRUG:** Evolocumab Drug Substance A (Test)
- **DRUG:** Evolocumab Drug Substance B (Reference)

## Key facts

- **NCT ID:** NCT07545226
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-20
- **Primary completion:** 2026-09-08
- **Final completion:** 2026-09-08
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2026-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07545226

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07545226, "Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07545226. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*